{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:59:48Z","timestamp":1772024388679,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/2047-783x-18-53","type":"journal-article","created":{"date-parts":[[2013,12,5]],"date-time":"2013-12-05T21:01:39Z","timestamp":1386277299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["RETRACTED ARTICLE: Systematic study of cilostazol on secondary stroke prevention: a meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Yining","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,6]]},"reference":[{"key":"81_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1161\/01.STR.26.3.392","volume":"26","author":"H Henon","year":"1995","unstructured":"Henon H, Godefroy O, Leys D, Mounier-Vehier F, Lucas C, Rondepierre P, Duhamel A, Pruvo J: Early predictors of death and disability after acute cerebral ischemic event. Stroke 1995, 26: 392\u2013398. 10.1161\/01.STR.26.3.392","journal-title":"Stroke"},{"key":"81_CR2","doi-asserted-by":"publisher","first-page":"e2158","DOI":"10.1371\/journal.pone.0002158","volume":"3","author":"H Harms","year":"2008","unstructured":"Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, G\u00f6hler J, Bereswill S, G\u00f6bel U, Wernecke KD: Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PloS One 2008, 3: e2158. 10.1371\/journal.pone.0002158","journal-title":"PloS One"},{"key":"81_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","unstructured":"Antiplatelet Trialists\u2019 Collaboration: Collaborative overview of randomised trials of antiplatelet therapy.I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308: 81\u2013106.","journal-title":"BMJ"},{"key":"81_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1159\/000120687","volume":"25","author":"J Rother","year":"2008","unstructured":"Rother J, Alberts MJ, Touze E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D\u2019Agostino R, Hirsch AT, Wilson PW, Steg PG: Risk factor profile and management of cerebrovascular patients in the REACH Registry. Cerebrovasc Dis 2008, 25: 366\u2013374. 10.1159\/000120687","journal-title":"Cerebrovasc Dis"},{"key":"81_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jama.280.22.1930","volume":"280","author":"J He","year":"1998","unstructured":"He J, Whelton PK, Vu B, Klag MJ: Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998, 280: 1930\u20131935. 10.1001\/jama.280.22.1930","journal-title":"JAMA"},{"key":"81_CR6","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1161\/01.STR.0000090348.52943.A2","volume":"34","author":"M Kubo","year":"2003","unstructured":"Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003, 34: 2349\u20132354. 10.1161\/01.STR.0000090348.52943.A2","journal-title":"Stroke"},{"key":"81_CR7","doi-asserted-by":"publisher","first-page":"I29","DOI":"10.1161\/01.STR.23.6.839","volume":"23","author":"S Levine","year":"1992","unstructured":"Levine S, Brey R, Joseph C, Havstad S: Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The antiphospholipid antibodies in stroke study group. Stroke 1992, 23: I29.","journal-title":"Stroke"},{"key":"81_CR8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1161\/01.STR.31.7.1770","volume":"31","author":"PM Bath","year":"2000","unstructured":"Bath PM, Iddenden R, Bath FJ: Low-molecular-weight heparins and heparinoids in acute ischemic stroke a meta-analysis of randomized controlled trials. Stroke 2000, 31: 1770\u20131778. 10.1161\/01.STR.31.7.1770","journal-title":"Stroke"},{"key":"81_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/ane.12111","volume":"128","author":"MD Mijajlovic","year":"2013","unstructured":"Mijajlovic MD, Shulga O, Bloch S, Covickovic-Sternic N, Aleksic V, Bornstein NM: Clinical consequences of aspirin and clopidogrel resistance: an overview. Acta Neurologica Scandinavica 2013, 128: 213\u2013219. 10.1111\/ane.12111","journal-title":"Acta Neurologica Scandinavica"},{"key":"81_CR10","first-page":"CD008076","volume":"1","author":"AK Kamal","year":"2011","unstructured":"Kamal AK, Naqvi I, Husain MR, Khealani BA: Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011, 1: CD008076.","journal-title":"Cochrane Database Syst Rev"},{"key":"81_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1053\/jscd.2000.7216","volume":"9","author":"F Gotoh","year":"2000","unstructured":"Gotoh F, Tohgi H, Hirai S, Terashi A, Fukuuchi Y, Otomo E, Shinohara Y, Itoh E, Matsuda T, Sawada T: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000, 9: 147\u2013157. 10.1053\/jscd.2000.7216","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"81_CR12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.4103\/0253-7176.101776","volume":"34","author":"DS Patel","year":"2012","unstructured":"Patel DS, Anand IS, Bhatt PA: Evaluation of antidepressant and anxiolytic activity of phosphodiesterase 3 inhibitor - cilostazol. Indian J Psychol Med 2012, 34: 124\u2013128. 10.4103\/0253-7176.101776","journal-title":"Indian J Psychol Med"},{"key":"81_CR13","first-page":"541","volume":"54","author":"S Hatano","year":"1976","unstructured":"Hatano S: Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976, 54: 541\u2013553.","journal-title":"Bull World Health Organ"},{"key":"81_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000327036","volume":"32","author":"YS Lee","year":"2011","unstructured":"Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS: Cilostazol in acute ischemic stroke treatment (CAIST trial): a randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011, 32: 65\u201371. 10.1159\/000327036","journal-title":"Cerebrovasc Dis"},{"key":"81_CR15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","volume":"9","author":"Y Shinohara","year":"2010","unstructured":"Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010, 9: 959\u2013968. 10.1016\/S1474-4422(10)70198-8","journal-title":"Lancet Neurol"},{"key":"81_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12264-009-6192-2","volume":"25","author":"JJ Guo","year":"2009","unstructured":"Guo JJ, Xu E, Lin QY, Zeng GL, Xie HF: Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. Neurosci Bull 2009, 25: 383\u2013390. 10.1007\/s12264-009-6192-2","journal-title":"Neurosci Bull"},{"key":"81_CR17","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","volume":"7","author":"Y Huang","year":"2008","unstructured":"Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C: Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008, 7: 494\u2013499. 10.1016\/S1474-4422(08)70094-2","journal-title":"Lancet Neurol"},{"key":"81_CR18","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/01.STR.0000157667.06542.b7","volume":"36","author":"SU Kwon","year":"2005","unstructured":"Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS: Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005, 36: 782\u2013786. 10.1161\/01.STR.0000157667.06542.b7","journal-title":"Stroke"},{"key":"81_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/STR.0b013e3181f7d043","volume":"42","author":"KL Furie","year":"2011","unstructured":"Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D: Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke 2011, 42: 227\u2013276. 10.1161\/STR.0b013e3181f7d043","journal-title":"Stroke"},{"issue":"Suppl 1","key":"81_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1159\/000074800","volume":"17","author":"LA Urbano","year":"2004","unstructured":"Urbano LA, Bogousslavsky J: Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Cerebrovasc Dis 2004, 17(Suppl 1):74\u201380.","journal-title":"Cerebrovasc Dis"},{"key":"81_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/ajh.10150","volume":"71","author":"A Symeonidis","year":"2002","unstructured":"Symeonidis A, Kouraklis-Symeonidis A, Seimeni U, Galani A, Giannakoulas N, Fragopanagou E, Tiniakou M, Matsouka P, Zoumbos N: Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol 2002, 71: 24\u201332. 10.1002\/ajh.10150","journal-title":"Am J Hematol"},{"key":"81_CR22","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/01.STR.19.10.1203","volume":"19","author":"M Gent","year":"1988","unstructured":"Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Design, organization, and baseline results. Stroke 1988, 19: 1203\u20131210. 10.1161\/01.STR.19.10.1203","journal-title":"Stroke"},{"key":"81_CR23","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","volume":"95","author":"VL Serebruany","year":"2005","unstructured":"Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ: Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005, 95: 1218\u20131222. 10.1016\/j.amjcard.2005.01.049","journal-title":"Am J Cardiol"},{"key":"81_CR24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1345\/aph.1Q420","volume":"46","author":"AJ Ansara","year":"2012","unstructured":"Ansara AJ, Shiltz DL, Slavens JB: Use of cilostazol for secondary stroke prevention: an old dog with new tricks? Ann Pharmacother 2012, 46: 394\u2013402. 10.1345\/aph.1Q420","journal-title":"Ann Pharmacother"},{"key":"81_CR25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0037-1615863","volume":"82","author":"Y Ikeda","year":"1999","unstructured":"Ikeda Y: Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 1999, 82: 435\u2013438.","journal-title":"Thromb Haemost"},{"key":"81_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosissup.2005.09.002","volume":"6","author":"S Goto","year":"2005","unstructured":"Goto S: Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis Suppl 2005, 6: 3\u201311.","journal-title":"Atherosclerosis Suppl"},{"key":"81_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","volume":"19","author":"Y Liu","year":"2001","unstructured":"Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J: Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001, 19: 369\u2013386.","journal-title":"Cardiovasc Drug Rev"},{"key":"81_CR28","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.2174\/1381612033453910","volume":"9","author":"J Kambayashi","year":"2003","unstructured":"Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003, 9: 2289\u20132302. 10.2174\/1381612033453910","journal-title":"Curr Pharm Des"},{"key":"81_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4103\/2152-7806.76145","volume":"2","author":"Y Kai","year":"2011","unstructured":"Kai Y, Watanabe M, Morioka M, Hirano T, Yano S, Ohmori Y, Kawano T, Hamada J, Kuratsu J: Cilostazol improves symptomatic intracranial artery stenosis - evaluation of cerebral blood flow with single photon emission computed tomography. Surg Neurol International 2011, 2: 8. 10.4103\/2152-7806.76145","journal-title":"Surg Neurol International"},{"key":"81_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","volume":"109","author":"C Lugnier","year":"2006","unstructured":"Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109: 366\u2013398. 10.1016\/j.pharmthera.2005.07.003","journal-title":"Pharmacol Ther"},{"key":"81_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2174\/157016110791112331","volume":"8","author":"F Sallustio","year":"2010","unstructured":"Sallustio F, Rotondo F, Di Legge S, Stanzione P: Cilostazol in the management of atherosclerosis. Curr Vasc Pharmacol 2010, 8: 363\u2013372. 10.2174\/157016110791112331","journal-title":"Curr Vasc Pharmacol"},{"key":"81_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s00125-001-0740-2","volume":"45","author":"T Shinoda-Tagawa","year":"2002","unstructured":"Shinoda-Tagawa T, Yamasaki Y, Yoshida S, Kajimoto Y, Tsujino T, Hakui N, Matsumoto M, Hori M: A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia 2002, 45: 188\u2013194. 10.1007\/s00125-001-0740-2","journal-title":"Diabetologia"},{"key":"81_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1161\/01.CIR.102.3.313","volume":"102","author":"PJ Touboul","year":"2000","unstructured":"Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, Amarenco P: Common carotid artery intima-media thickness and brain infarction: the Etude du Profil Genetique de l\u2019Infarctus Cerebral (GENIC) case\u2013control study. The GENIC Investigators. Circulation 2000, 102: 313\u2013318. 10.1161\/01.CIR.102.3.313","journal-title":"Circulation"},{"key":"81_CR34","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1161\/01.STR.0000091393.32060.0E","volume":"34","author":"M Hollander","year":"2003","unstructured":"Hollander M, Hak AE, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Witteman JC, Breteler MM: Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam study. Stroke 2003, 34: 2367\u20132372. 10.1161\/01.STR.0000091393.32060.0E","journal-title":"Stroke"},{"key":"81_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S0741-5214(03)01029-2","volume":"38","author":"DB Wilhite","year":"2003","unstructured":"Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK: Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003, 38: 710\u2013713. 10.1016\/S0741-5214(03)01029-2","journal-title":"J Vasc Surg"}],"updated-by":[{"DOI":"10.1186\/s40001-015-0125-5","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"record-id":"2025"},{"DOI":"10.1186\/2047-783x-18-53","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2013,12,6]],"date-time":"2013-12-06T00:00:00Z","timestamp":1386288000000}},{"DOI":"10.1186\/s40001-015-0125-5","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000}}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2047-783X-18-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/2047-783X-18-53","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/2047-783X-18-53.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:03:46Z","timestamp":1772021026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/2047-783X-18-53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,6]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,12]]}},"alternative-id":["81"],"URL":"https:\/\/doi.org\/10.1186\/2047-783x-18-53","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,6]]},"assertion":[{"value":"25 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"53"}}